Article
NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
31 Jan 2022
Abstract excerpt
The lack of neuroprotective treatments for retinal ganglion cells (RGCs) and optic nerve (ON) is a central challenge for glaucoma management. Emerging evidence suggests that redox factor NAD + decline is a hallmark of aging and neurodegenerative diseases. Supplementation with NAD + precursors and overexpression of NMNAT1, the key enzyme in the NAD + biosynthetic process, have significant neuroprotective effects....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.